Rezultati - Koitka‐Weber, Audrey

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME(®) trial od Kadowaki, Takashi, Nangaku, Masaomi, Hantel, Stefan, Okamura, Tomoo, von Eynatten, Maximilian, Wanner, Christoph, Koitka‐Weber, Audrey

Polni tekst Polni tekst Polni tekst

Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial od Levin, Adeera, Perkovic, Vlado, Wheeler, David C., Hantel, Stefan, George, Jyothis T., von Eynatten, Maximilian, Koitka-Weber, Audrey, Wanner, Christoph

Polni tekst Polni tekst Polni tekst

Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin–angiotensin system inhibitors in type 2 diabetic patients with albuminuria od Cooper, Mark E., Perkovic, Vlado, Groop, Per-Henrik, Hocher, Berthold, Hehnke, Uwe, Meinicke, Thomas, Koitka-Weber, Audrey, van der Walt, Sandra, von Eynatten, Maximilian

Polni tekst Polni tekst Polni tekst

Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes od Ruggenenti, Piero, Kraus, Bettina J., Inzucchi, Silvio E., Zinman, Bernard, Hantel, Stefan, Mattheus, Michaela, von Eynatten, Maximilian, Remuzzi, Giuseppe, Koitka-Weber, Audrey, Wanner, Christoph

Polni tekst Polni tekst Polni tekst

Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial od Waijer, Simke W., Xie, Di, Inzucchi, Silvio E., Zinman, Bernard, Koitka‐Weber, Audrey, Mattheus, Michaela, von Eynatten, Maximillian, Inker, Lesley A., Wanner, Christoph, Heerspink, Hiddo J. L.

Polni tekst Polni tekst Polni tekst

Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial od Ferreira, João Pedro, Kraus, Bettina Johanna, Zwiener, Isabella, Lauer, Sabine, Zinman, Bernard, Fitchett, David H., Koitka‐Weber, Audrey, George, Jyothis T., Ofstad, Anne Pernille, Wanner, Christoph, Zannad, Faiez

Polni tekst Polni tekst Polni tekst

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial od Wanner, Christoph, Heerspink, Hiddo J.L., Zinman, Bernard, Inzucchi, Silvio E., Koitka-Weber, Audrey, Mattheus, Michaela, Hantel, Stefan, Woerle, Hans-Juergen, Broedl, Uli C., von Eynatten, Maximilian, Groop, Per-Henrik

Polni tekst Polni tekst Polni tekst

Disparate Effects of Diabetes and Hyperlipidemia on Experimental Kidney Disease od Watson, Anna M. D., Gould, Eleanor A. M., Moody, Sarah C., Sivakumaran, Priyadharshini, Sourris, Karly C., Chow, Bryna S. M., Koïtka-Weber, Audrey, Allen, Terri J., Jandeleit-Dahm, Karin A. M., Cooper, Mark E., Calkin, Anna C.

Polni tekst Polni tekst Polni tekst

Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA‐T2D trial od Groop, Per‐Henrik, Cooper, Mark E., Perkovic, Vlado, Hocher, Berthold, Kanasaki, Keizo, Haneda, Masakazu, Schernthaner, Guntram, Sharma, Kumar, Stanton, Robert C., Toto, Robert, Cescutti, Jessica, Gordat, Maud, Meinicke, Thomas, Koitka‐Weber, Audrey, Thiemann, Sandra, von Eynatten, Maximilian

Polni tekst Polni tekst Polni tekst